Other
EFFICACY AND SAFETY OF CERA IN ANEMIA CORRECTION IN PREDIALYSIS PATIENTS - CROATIAN EXPERIENCE
IVAN BUBIĆ
; Department of Nephrology and Dialysis, University Hospital Centre Rijeka, Rijeka, Croatia
INGRID PRKAČIN
; Department of Nephrology, Clinical Hospital Merkur, Zagreb, Croatia
SANJIN RAČKI
; Department of Nephrology and Dialysis, University Hospital Centre Rijeka, Rijeka, Croatia
Abstract
Aim: to evaluate efficacy and safety of cera (continuous erythropoietin receptor activator) administration for correcting anemia in the patients with chronic kidney disease (ckd), not on dialysis. methods: We performed observational study on 27 ckd patients in stage 4 or 5 with renal anemia requiring use of erythropoiesis-stimulating agents (esa). all patients received cera (mircera®; roche, basel, switzerland) subcutaneously in dose of 0.6 μg per kg very two weeks during the correction phase of anemia treatment or once monthly during the maintenance treatment. dose of cera was modified according to manufacturer instructions. iron supplementation was administrated orally or intravenously in order to achieve serum ferritin 200-500 μg/L. Patients were followed up to 1 year (from 3-12 months). response riteria for cera were Hb increase
Keywords
anemia; cera; kidney failure; chronic
Hrčak ID:
99538
URI
Publication date:
3.4.2013.
Visits: 1.514 *